DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
968
TRX-1
2
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell surface antigen CD4 inhibitor
TRX-1
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PAGIBAXIMAB
2
Antibody
Investigational
Unknown
Unknown
Sepsis
Lipoteichoic acid inhibitor
PAGIBAXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CACP29
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
CACP29
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MODOTUXIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MODOTUXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
1W7BD1M08N
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HUJ591 177LU
2
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant
Glutamate carboxypeptidase II binding agent
HUJ591 177LU
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FPA144
2
Antibody
Investigational
Unknown
Unknown
Stomach Neoplasms
Fibroblast growth factor receptor 2 inhibitor
FPA144
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
REGDANVIMAB
2
Antibody
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Unknown
REGDANVIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZANOLIMUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lymphoma; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome
T-cell surface antigen CD4 other
ZANOLIMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
HG3L8885M0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LABETUZUMAB GOVITECAN
2
Antibody
Investigational
Unknown
Unknown
Colonic Neoplasms; Rectal Neoplasms
Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent
LABETUZUMAB GOVITECAN
×
Maximum Phase:
2
First Approval:
None
UNII:
8E3HI6QQ9J
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ENOBLITUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Melanoma; Carcinoma, Squamous Cell; Prostatic Neoplasms, Castration-Resistant
CD276 antigen cross-linking agent
ENOBLITUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
M6030H73N9
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SONEPCIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Renal Cell; Macular Degeneration
Sphingosine 1-phosphate inhibitor
SONEPCIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
O4T5UXS4P2
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PRALUZATAMAB RAVTANSINE
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms
CD166 antigen binding agent
PRALUZATAMAB RAVTANSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
RD2I59M9FC
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LARCAVIXIMAB
2
Antibody
Investigational
Unknown
Unknown
Hemorrhagic Fever, Ebola
Unknown
LARCAVIXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
181UPT812X
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GATIPOTUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
GATIPOTUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
85V55ZLV2Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RIPERTAMAB
2
Antibody
Investigational
Unknown
Unknown
Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse
Unknown
RIPERTAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
URS0374MIV
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CADONILIMAB
2
Antibody
Investigational
Unknown
Unknown
Lung Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Nasopharyngeal Neoplasms; Neoplasms; Uterine Cervical Neoplasms
Cytotoxic T-lymphocyte protein 4 inhibitor
CADONILIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SGN-15
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Prostatic Neoplasms
Lewis Y antigen binding agent
SGN-15
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
APOMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Tumor necrosis factor receptor superfamily member 10B agonist
APOMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
703KLX5LXZ
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VOLAGIDEMAB
2
Antibody
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2; Hyperglycemia; Diabetes Mellitus, Type 1
Glucagon receptor inhibitor
VOLAGIDEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
77JYS6UZ0M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MK-4721
2
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant; Carcinoma, Pancreatic Ductal; Digestive System Diseases
Prostate stem cell antigen inhibitor
MK-4721
×
Maximum Phase:
2
First Approval:
None
UNII:
L0505LPC7O
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CAMIDANLUMAB TESIRINE
2
Antibody
Investigational
Unknown
Unknown
Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hodgkin Disease; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
DNA cross-linking agent
CAMIDANLUMAB TESIRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
LYJ1AEJ9YH
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BB-10901
2
Antibody
Investigational
Unknown
Unknown
Multiple Myeloma; Small Cell Lung Carcinoma
Neural cell adhesion molecule 1 binding agent
BB-10901
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GC1118
2
Antibody
Investigational
Unknown
Unknown
Glioblastoma; Stomach Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
GC1118
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CLENOLIXIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell surface antigen CD4 inhibitor
CLENOLIXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SCH-708980
2
Antibody
Investigational
Unknown
Unknown
Leishmaniasis
Interleukin-10 inhibitor
SCH-708980
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ASCRINVACUMAB
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms; Neoplasms; Carcinoma, Hepatocellular; Mesothelioma
Serine/threonine-protein kinase receptor R3 inhibitor
ASCRINVACUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
716FQ5REVO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PD-360324
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lupus Erythematosus, Cutaneous; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Sarcoidosis, Pulmonary
Macrophage colony-stimulating factor 1 inhibitor
PD-360324
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LY2541546
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
LY2541546
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MELRILIMAB
2
Antibody
Investigational
Unknown
Unknown
Asthma
Unknown
MELRILIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
26C72EGQ3G
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SETRUSUMAB
2
Antibody
Investigational
Unknown
Unknown
Hypophosphatasia; Kidney Diseases; Osteogenesis Imperfecta
Sclerostin inhibitor
SETRUSUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
FPW3780T3E
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HUJ591 111IN
2
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant
Glutamate carboxypeptidase II binding agent
HUJ591 111IN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
STX-100
2
Antibody
Investigational
Unknown
Unknown
Idiopathic Pulmonary Fibrosis
Integrin alpha-V/beta-6 inhibitor
STX-100
×
Maximum Phase:
2
First Approval:
None
UNII:
JD43Y6YF3N
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TEFIBAZUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Clumping factor A inhibitor
TEFIBAZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
SBO7Q9G95R
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LERONLIMAB
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Graft vs Host Disease; HIV Infections; Neoplasms; Non-alcoholic Fatty Liver Disease; Severe Acute Respiratory Syndrome
C-C chemokine receptor type 5 antagonist
LERONLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
Y1J4NP8FF0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
XTL-6865
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
XTL-6865
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
14
15
16
17
18
19
20
…
27
28
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA